CTLA4 and neuroendocrine neoplasm: The average number of participating centers per trial was 56, with the highest number 1,013 centers, reported in the Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) study targeting neuroendocrine tumors.